COMPANY

Corporate History

April 2002 Acugen Neuropeutics Inc. was established in Seattle, Washington USA, under the laws of State of Washington to develop methods of the treatment for degenerative eye diseases and pharmaceutical compound screening system
March 2003 Acugen Neuropeutics Inc. renamed as Acucela Inc.
Oct. 2005 Initiated Visual Cycle Modulation (VCM) development
March 2006 Relocation of Acucela headquarters to Bothell, Washington
April 2006 Initiated development for emixustat, the lead VCM-based product candidate for the treatment of retinal diseases
Aug. 2006 Opened the Tokyo Office in Shinagawa ward in Tokyo
May 2008 The Investigational New Drug (IND) for emixustat for geographic atrophy secondary to dry age-related macular Degeneration (AMD) was filed with the US Food and Drug Administration (FDA)
June 2008 Initiated Phase 1 clinical trial of emixustat for geographic atrophy secondary to dry AMD
Sept. 2008 Announced co-development and commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for emixustat
March 2010 Announced FDA Fast Track designation for emixustat for geographic atrophy secondary to dry AMD
Sept. 2010 Announced relocation of headquarters to Seattle, Washington
April 2013 Initiated Phase 2/3b clinical trial of emixustat for geographic atrophy secondary to dry AMD
Sept. 2013 Tokyo Office relocated to Shibuya ward in Tokyo
Feb. 2014 Initial Public Offering on Tokyo Stock Exchange Mothers Board
May 2015 Announced publication of pre-clinical data of emixustat for geographic atrophy secondary to dry AMD
June 2015 Announced publication of results from Phase 2a clinical trial of emixustat for geographic atrophy secondary to dry AMD
Dec. 2015 Incorporated a subsidiary, Acucela Japan KK (current Kubota Pharmaceutical Holdings Co., Ltd.) in Japan
March 2016 Announced an exclusive option to license novel cataract treatment
April 2016 Announced an exclusive license agreement for gene therapy from the University of Manchester for retinal degenerative disease
May 2016 Initiates Phase 2 clinical trial for proliferative diabetic retinopathy
May 2016 Announced top-line results from Phase 2b/3 clinical trial of emixustat for geographic atrophy secondary to dry AMD
June 2016 Announced the termination of co-development and promotion agreement with Otsuka Pharmaceutical Co., Ltd.
Dec. 2016 Completed the triangle merger and the redomicile transaction; Acucela Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd.
Dec. 2016 Kubota Pharmaceutical Holdings Co., Ltd. listed on the Tokyo Stock Exchange Mothers Board
Dec. 2016 Announced R&D agreement to exclusively acquire novel retinal technology from EyeMedics
Jan. 2017 Announced FDA orphan drug designation for emixustat for Stargardt disease
Jan. 2017 Initiated Phase 2a clinical trial of emixustat for Stargardt disease
Feb. 2017 Initiated development for remote medical monitoring device
June 2017 Tokyo Office relocated to Chiyoda ward in Tokyo
Jan. 2018 Announced a two-year development agreement with SIRION Biotech GmbH on gene delivery tools for ocular gene therapy
Jan. 2018 Announced results from Phase 2 clinical trial of emixustat for proliferative diabetic retinopathy
Jan. 2018 Announced results from Phase 2a clinical trial of emixustat for Stargardt disease
March 2018 Announced initiation of clinical trial for PBOS device
Nov. 2018 Announced PBOS device clinical trial results
Nov. 2018 Initiated Phase 3 clinical trial of emixustat for Stargardt disease